• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Waldencast plc

    2/1/24 5:17:40 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $WALD alert in real time by email
    SC 13G 1 tm244934d1_sc13g.htm SC 13G

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.           )*

     

    Waldencast PLC

    (Name of Issuer as Specified in its Certificate of Incorporation)

     

    Class A Ordinary Shares

    (Title of Class of Securities)

     

    G9503X103

    (CUSIP Number)

     

    September 14, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP No.          G9503X103  

     

    1

    Names of Reporting Persons

     

    Santa Venerina Inv. & Arbitrage Ltd.

    2

    Check the appropriate box if a member of a Group (see instructions)

     

    (a)   ¨

    (b)   ¨

    3

    Sec Use Only

     

     

    4

    Citizenship or Place of Organization

     

    The Commonwealth of the Bahamas

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:
    5

    Sole Voting Power

     

    10,000,000

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    10,000,000

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    10,000,000

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    ¨

    11

    Percent of class represented by amount in row (9) 

     

    9.9%1

    12

    Type of Reporting Person (See Instructions)

     

    OO

           

     

    1 Based on 101,228,857 Class A ordinary shares outstanding as of December 31, 2023, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission on January 16, 2024.

     

    2

     

     

    Item 1(a).   Name of Issuer:

     

    Waldencast PLC

     

    Item 1(b).   Address of Issuer’s Principal Executive Offices:

     

    10 Bank Street, Suite 560, White Plains, NY 10606

     

    Item 2.

     

    (a)Name of Person Filing:

     

    Santa Venerina Inv. & Arbitrage Ltd.

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    East Bay Street, P.O, Box N-7757, Nassau, The Bahamas

     

    (c)Citizenship:

     

    The Commonwealth of the Bahamas

     

    (d)Title and Class of Securities:

     

    Class A Ordinary Shares

     

    (e)CUSIP No.:

     

    G9503X103

     

    Item 3.If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨  Broker or dealer registered under Section 15 of the Act;

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act;

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act;

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940;

     

    (e)¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act.;

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940;

     

    (j)¨ Group, in accordance with § 240 240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:           

     

    3

     

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.

     

    (a)            Amount Beneficially Owned:         10,000,000

     

    (b)            Percent of Class: 9.9%2

     

    (c)            Number of shares as to which such person has:

     

    (i)            Sole power to vote or to direct the vote: 10,000,000

     

    (ii)           Shared power to vote or to direct the vote: 0

     

    (iii)          Sole power to dispose or to direct the disposition of: 10,000,000

     

    (iv)          Shared power to dispose or to direct the disposition of: 0

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of more than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

     

    Not applicable

     

    Item 8.Identification and classification of members of the group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

    2 Based on 101,228,857 Class A ordinary shares outstanding as of December 31, 2023, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission on January 16, 2024.

     

    4

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

        Dated: February 1, 2024  Santa Venerina Inv. & Arbitrage Ltd.
        
       Signature: /s/ Philipp Kieber
        
       Name/Title: Philipp Kieber, Secretary

     

    5

    Get the next $WALD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WALD

    DatePrice TargetRatingAnalyst
    1/14/2026$2.00Buy
    Jefferies
    11/25/2025$3.00Outperform → Market Perform
    Telsey Advisory Group
    4/22/2025$5.00Buy
    Alliance Global Partners
    12/16/2024$4.30Hold
    TD Cowen
    10/25/2024$5.00Buy
    Canaccord Genuity
    5/1/2024$10.00 → $8.00Outperform
    Telsey Advisory Group
    7/24/2023Outperform → Mkt Perform
    Raymond James
    9/9/2022$12.00Buy
    DA Davidson
    More analyst ratings

    $WALD
    SEC Filings

    View All

    SEC Form 6-K filed by Waldencast plc

    6-K - Waldencast plc (0001840199) (Filer)

    3/13/26 6:47:02 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 20-F filed by Waldencast plc

    20-F - Waldencast plc (0001840199) (Filer)

    3/13/26 6:46:32 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 6-K filed by Waldencast plc

    6-K - Waldencast plc (0001840199) (Filer)

    3/11/26 4:16:12 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin's Age and Restore Visible Youthfulness

    NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Obagi Medical ("Obagi"), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), is proud to announce the latest innovation in advanced skin science and longevity with the launch of its newest breakthrough: Obagi NU-GEN™ Cellular Renewal Serum. A cellular renewal serum that acts like a power supply for your skin and supports its natural cellular functions. The formula is clinically proven to visibly rewind skin's age by up to six years1 by helping replenish skin cells with NAD+ and addressing nine signs of skin aging simultaneously. At the cor

    3/24/26 8:35:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™

    NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced a collaboration with ProMD Health as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. ProMD was selected for its strong multi-location network of 17 practices and its commitment to clinical excellence, making it an ideal evaluator to rigorously examine Obagi® saypha® MagIQ™ alongside comprehensive skincare protocols across its multi-state provider base. Through this collaboration, ProMD providers will participate in a structured evaluat

    3/19/26 8:29:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast Reports Q4 2025 and FY 2025 Financial Results

    FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing o

    3/13/26 6:50:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Brousset Michel

    3 - Waldencast plc (0001840199) (Issuer)

    3/18/26 12:12:49 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 3 filed by new insider Souza Cristiano

    3 - Waldencast plc (0001840199) (Issuer)

    3/18/26 11:25:15 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 3 filed by new insider Thompson Motta Roberto Moses

    3 - Waldencast plc (0001840199) (Issuer)

    3/18/26 11:24:08 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Waldencast plc with a new price target

    Jefferies resumed coverage of Waldencast plc with a rating of Buy and set a new price target of $2.00

    1/14/26 8:45:39 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast plc downgraded by Telsey Advisory Group with a new price target

    Telsey Advisory Group downgraded Waldencast plc from Outperform to Market Perform and set a new price target of $3.00

    11/25/25 8:37:06 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Alliance Global Partners initiated coverage on Waldencast plc with a new price target

    Alliance Global Partners initiated coverage of Waldencast plc with a rating of Buy and set a new price target of $5.00

    4/22/25 9:24:54 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Leadership Updates

    Live Leadership Updates

    View All

    Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™

    NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced a collaboration with ProMD Health as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. ProMD was selected for its strong multi-location network of 17 practices and its commitment to clinical excellence, making it an ideal evaluator to rigorously examine Obagi® saypha® MagIQ™ alongside comprehensive skincare protocols across its multi-state provider base. Through this collaboration, ProMD providers will participate in a structured evaluat

    3/19/26 8:29:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Shareholders Elect Four Independent Directors to the Six Flags Board

    Six Flags Entertainment Corporation (NYSE:FUN), the largest regional amusement park operator in North America, announced today that its shareholders elected Sandra (Sandy) Cochran, Michael Colglazier, Felipe Dutra, and Steven Hoffman to the Board of Directors of Six Flags Entertainment Corporation for 3-year terms expiring in 2028. Shareholders also confirmed the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm, approved an advisory vote on the compensation of the Company's named executive officers, and confirmed a 1-year frequency for shareholder advisory votes on executive compensation. "I want to welcome Sandy, Michael, Felipe and St

    6/25/25 5:00:00 PM ET
    $BUD
    $CBRL
    $DG
    Beverages (Production/Distribution)
    Consumer Staples
    Restaurants
    Consumer Discretionary

    Milk Makeup to Launch at Ulta Beauty This Spring

    The New York City based award-winning clean color cosmetics brand will expand to select Ulta Beauty stores nationwide and online, marking a significant milestone since its debut in 2016 NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Milk Makeup, the trailblazing clean beauty brand celebrated for its iconic, high-performance formulas, inclusive ethos and part of the Waldencast plc (NASDAQ:WALD) platform, is thrilled to announce an expansion into the nation's largest beauty retailer, Ulta Beauty. Beginning this spring, Milk Makeup's cult-favorite products, including the 13x award-winning Hydro Grip Primer and internet-breaking Cooling Water Jelly Tints will be available in 600+ Ulta Beauty stores nat

    1/28/25 6:45:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Financials

    Live finance-specific insights

    View All

    Waldencast Reports Q4 2025 and FY 2025 Financial Results

    FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing o

    3/13/26 6:50:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date

    LONDON, March 11, 2026 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform announced that its Fourth Quarter and Fiscal Year 2025 earnings will be issued in a press release on March 13, 2026, prior to U.S. market open. The Company does not plan to host a conference call to discuss results given its ongoing strategic review. About Waldencast plc Founded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned

    3/11/26 4:05:00 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update

    Transformation efforts drive performance improvements at Obagi Medical with accelerating revenue Contrasted performance for Milk Makeup with Q2 2025 net revenue growth driven by U.S. channel expansion and sell-out acceleration but softer performance in Q3 2025 in international markets Company advances key strategic initiatives, including expansion into medical aesthetics through the Novaestiq acquisition and strengthened balance sheet following the sale of the Obagi Japan trademark and credit facility refinancing Waldencast updates FY 2025 guidance to reflect current trends and purposeful investments to drive long-term growth LONDON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NA

    11/24/25 6:45:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Waldencast plc (Amendment)

    SC 13D/A - Waldencast plc (0001840199) (Subject)

    2/9/24 6:25:08 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13G filed by Waldencast plc

    SC 13G - Waldencast plc (0001840199) (Subject)

    2/1/24 5:17:40 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13G/A filed by Waldencast plc (Amendment)

    SC 13G/A - Waldencast plc (0001840199) (Subject)

    1/31/24 10:23:25 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary